Hampstead Capital’s Pfizer PFE Stock Holding History

Hampstead Capital’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	$3.93M	Sell	94,017 -14,650	-13%	-$564K	7.04%	7
2018 Q2	$3.74M	Sell	108,667 -4,427	-4%	-$151K	7.03%	9
2018 Q1	$3.81M	Sell	113,094 -4,532	-4%	-$156K	5.12%	7
2017 Q4	$4.04M	Buy	117,626 +14,545	+14%	+$496K	5.05%	4
2017 Q3	$3.49M	Sell	103,081 -97,179	-49%	-$3.12M	3.46%	12
2017 Q2	$6.38M	Sell	200,260 -22,239	-10%	-$701K	6.28%	2
2017 Q1	$7.22M	Sell	222,499 -12,227	-5%	-$386K	7.47%	2
2016 Q4	$7.23M	Buy	+234,726	New	+$7.17M	7.67%	1

Other funds holding PFE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Hampstead Capital's PFE Position: Q3 2018 in Review

Hampstead Capital reduced its Pfizer (PFE) stake by 13% in Q3 2018, selling an estimated $564K and leaving 94,017 shares worth $3.93M. The position accounts for 7.04% of the portfolio, ranked #7.

Hampstead Capital first reported a position in PFE in Q4 2016 and has held it in 8 quarters since. The position peaked at $7.23M in Q4 2016. 2,257 funds tracked by Wall St. Rank hold PFE as of Q3 2018.

Hampstead Capital held 94,017 shares of Pfizer worth $3.93M as of Q3 2018.
Hampstead Capital sold 14,650 Pfizer shares in Q3 2018, an estimated $564K.
Pfizer made up 7.04% of Hampstead Capital's portfolio in Q3 2018, its #7 holding.
Hampstead Capital first reported a position in Pfizer in Q4 2016 and has held it in 8 quarters since.
Hampstead Capital's Pfizer position peaked at $7.23M in Q4 2016.
2,257 funds tracked by Wall St. Rank held Pfizer as of Q3 2018.

Based on Hampstead Capital's 13F filing for Q3 2018, filed 14 Nov 2018.